Favorable prognostic impact of Natural Killer cells and T cells in high-grade serous ovarian carcinoma

References

• Seidman JD, Horkayne-Szakaly I, Haiba M, et al. The histologic type and stage distribution of ovarian carcinomas of surface epithelial origin. Int J Gynecol Pathol. 2004;23(1):41–44.
   PubMed Web of Science ®Google Scholar
• Ledermann JA, Raja FA, Fotopoulou C, et al. Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2013;24(Suppl. 6):vi24–vi32.
   PubMed Web of Science ®Google Scholar
• Topalian SL, Sznol M, McDermott DF, et al. Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. J Clin Oncol. 2014;32(10):1020–1030.
   PubMed Web of Science ®Google Scholar
• Gettinger SN, Horn L, Gandhi L, et al. Overall survival and long-term safety of nivolumab (anti-programmed death 1 antibody, BMS-936558, ONO-4538) in patients with previously treated advanced non-small-cell lung cancer. J Clin Oncol. 2015;33(18):2004–2012.
   PubMed Web of Science ®Google Scholar
• Wang W, Liu JR, Zou W. Immunotherapy in ovarian cancer. Surg Oncol Clin N Am. 2019;28(3):447–464.
   PubMed Web of Science ®Google Scholar
• Zhang L, Conejo-Garcia JR, Katsaros D, et al. Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N Engl J Med. 2003;348(3):203–213.
   PubMed Web of Science ®Google Scholar
• Ali HR, Provenzano E, Dawson SJ, et al. Association between CD8+ T-cell infiltration and breast cancer survival in 12 439 patients. Ann Oncol. 2014;25(8):1536–1543.
   PubMed Web of Science ®Google Scholar
• Mlecnik B, Tosolini M, Kirilovsky A, et al. Histopathologic-based prognostic factors of colorectal cancers are associated with the state of the local immune reaction. J Clin Oncol. 2011;29(6):610–618.
   PubMed Web of Science ®Google Scholar
• Sato E, Olson SH, Ahn J, et al. Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer. Proc Natl Acad Sci U S A. 2005;102(51):18538–18543.
   PubMed Web of Science ®Google Scholar
• Pinto MP, Balmaceda C, Bravo ML, et al. Patient inflammatory status and CD4+/CD8+ intraepithelial tumor lymphocyte infiltration are predictors of outcomes in high-grade serous ovarian cancer. Gynecol Oncol. 2018;151(1):10–17.
   PubMed Web of Science ®Google Scholar
• Goode EL, Sousa D. Dose–response relationship of CD8 + tumor infiltrating lymphocytes and survival time in high-grade serous ovarian cancer HHS public access. JAMA Oncol. 2017;3(12):173290.
   PubMed Web of Science ®Google Scholar
• Granier C, De Guillebon E, Blanc C, et al. Mechanisms of action and rationale for the use of checkpoint inhibitors in cancer. ESMO Open. 2017;2(2):e000213.
   PubMed Web of Science ®Google Scholar
• Met Ö, Jensen KM, Chamberlain CA, et al. Principles of adoptive T cell therapy in cancer. Semin Immunopathol. 2019;41(1):49–58.
   PubMed Web of Science ®Google Scholar
• Malmberg KJ, Carlsten M, Björklund A, et al. Natural Killer cell-mediated immunosurveillance of human cancer. Semin Immunol. 2017;31:20–29.
   PubMed Web of Science ®Google Scholar
• Chun-Wai Suen W, Yuk-Wai Lee W, Leung K-T, et al. Natural Killer cell-based cancer immunotherapy: a review on 10 years completed clinical trials. Cancer Invest. 2018;36(8):431–457.
   PubMed Web of Science ®Google Scholar
• Hu G, Wang S. Prognostic role of tumor-infiltrating CD57-positive lymphocytes in solid tumors: a meta-analysis. Oncotarget. 2018;9(8):8111–8119.
   PubMedGoogle Scholar
• Li K, Mandai M, Hamanishi J, et al. Clinical significance of the NKG2D ligands, MICA/B and ULBP2 in ovarian cancer: high expression of ULBP2 is an indicator of poor prognosis. Cancer Immunol Immunother. 2009;58(5):641–652.
   PubMed Web of Science ®Google Scholar
• Yan J, Kloecker G, Fleming C, et al. Human polymorphonuclear neutrophils specifically recognize and kill cancerous cells. Oncoimmunology. 2014;3(7):e950163.
   PubMed Web of Science ®Google Scholar
• Granot Z, Henke E, Comen EA, et al. Tumor entrained neutrophils inhibit seeding in the premetastatic lung. Cancer Cell. 2011;20(3):300–314.
   PubMed Web of Science ®Google Scholar
• Brandau S, Dumitru CA, Lang S. Protumor and antitumor functions of neutrophil granulocytes. Semin Immunopathol. 2013;35(2):163–176.
   PubMed Web of Science ®Google Scholar
• Murdoch C, Muthana M, Coffelt SB, et al. The role of myeloid cells in the promotion of tumour angiogenesis. Nat Rev Cancer. 2008;8(8):618–631.
   PubMed Web of Science ®Google Scholar
• Donskov F. Immunomonitoring and prognostic relevance of neutrophils in clinical trials. Semin Cancer Biol. 2013;23(3):200–207.
   PubMed Web of Science ®Google Scholar
• Shen M, Hu P, Donskov F, et al. Tumor-associated neutrophils as a new prognostic factor in cancer: a systematic review and meta-analysis. PLoS One. 2014;9(6):1–10.
   Web of Science ®Google Scholar
• Wang Q, Liu F, Liu L. Prognostic significance of PD-L1 in solid tumor: an updated meta-analysis. Medicine (Baltimore). 2017;96(18):e6369.
   PubMed Web of Science ®Google Scholar
• Hamanishi J, Mandai M, Iwasaki M, et al. Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancer. Proc Natl Acad Sci USA. 2007;104(9):3360–3365.
   PubMed Web of Science ®Google Scholar
• Santoiemma PP, Reyes C, Wang L-P, et al. Systematic evaluation of multiple immune markers reveals prognostic factors in ovarian cancer. Gynecol Oncol. 2016;143(1):120–127.
   PubMed Web of Science ®Google Scholar
• Darb-Esfahani S, Kunze CA, Kulbe H, et al. Prognostic impact of programmed cell death-1 (PD-1) and PD-ligand 1 (PD-L1) expression in cancer cells and tumor-infiltrating lymphocytes in ovarian high grade serous carcinoma. Oncotarget. 2015;7(2):1486–1499.
   Google Scholar
• Webb JR, Milne K, Kroeger DR, et al. PD-L1 expression is associated with tumor-infiltrating T cells and favorable prognosis in high-grade serous ovarian cancer. Gynecol Oncol. 2016;141(2):293–302.
   PubMed Web of Science ®Google Scholar
• Zhu X, Zhao L, Lang J. The BRCA1 methylation and PD-L1 expression in sporadic ovarian cancer. Int J Gynecol Cancer. 2018;28(8):1514–1519.
   PubMed Web of Science ®Google Scholar
•  Høgdall E, Høgdall C, Vo TT, et al. PD-L1 expression and prognosis significance in advanced ovarian cancer. Ann Oncol. 2017;28.
   Google Scholar
•  Høgdall CK, Petri AL. Dansk Gynaekologisk Cancer Database Årsrapport 2005 En Landsdaekkende Klinisk Database for Kraeft i Aeggestokke, Livmoder Og Livmoderhals [The Danish Gynecologic Cancer Database]; 2005.
   Google Scholar
• Hirsch FR, McElhinny A, Stanforth D, et al. PD-L1 immunohistochemistry assays for lung cancer: results from Phase 1 of the Blueprint PD-L1 IHC Assay Comparison Project. J Thorac Oncol. 2017;12(2):208–222.
   PubMed Web of Science ®Google Scholar
• Rimm DL, Han G, Taube JM, et al. A prospective, multi-institutional, pathologist-based assessment of 4 immunohistochemistry assays for PD-L1 expression in non-small cell lung cancer. JAMA Oncol. 2017;373(17):1051–1058.
   Web of Science ®Google Scholar
• Gao GF, Jakobsen BK. Molecular interactions of coreceptor CD8 and MHC class I: the molecular basis for functional coordination with the T-cell receptor. Immunol Today. 2000;21(12):630–636.
   PubMedGoogle Scholar
• Nielsen CM, White MJ, Goodier MR, et al. Functional significance of CD57 expression on human NK cells and relevance to disease. Front Immunol. 2013;4:422.
   PubMed Web of Science ®Google Scholar
• Lakschevitz FS, Hassanpour S, Rubin A, et al. Identification of neutrophil surface marker changes in health and inflammation using high-throughput screening flow cytometry. Exp Cell Res. 2016;342(2):200–209.
   PubMed Web of Science ®Google Scholar
• Carus A, Donskov F, Nielsen PS, et al. Strong prognostic value of tumor-infiltrating neutrophils and lymphocytes assessed by automated digital image analysis in early stage cervical cancer: a comparator study with observer-assisted stereological assessments. J OncoPathology. 2014;2(2):1–9.
   Google Scholar
• Eriksen AC, Andersen JB, Kristensson M, et al. Computer-assisted stereology and automated image analysis for quantification of tumor infiltrating lymphocytes in colon cancer. Diagn Pathol. 2017;12(1):65.
   PubMed Web of Science ®Google Scholar
• Gandini S, Massi D, Mandalà M. PD-L1 expression in cancer patients receiving anti PD-1/PD-L1 antibodies: a systematic review and meta-analysis. Crit Rev Oncol Hematol. 2016;100:88–98.
   PubMed Web of Science ®Google Scholar
• Piccart MJ. Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results. J Natl Cancer Inst. 2000;92(9):699–708.
   PubMed Web of Science ®Google Scholar
• Vasey PA, Jayson GC, Gordon A, et al. Phase III randomized trial of docetaxel-carboplatin versus paclitaxel-carboplatin as first-line chemotherapy for ovarian carcinoma. J Natl Cancer Inst. 2004;96(22):1682–1691.
   PubMed Web of Science ®Google Scholar
• Hamanishi J, Mandai M, Konishi I. Immune checkpoint inhibition in ovarian cancer. Int Immunol. 2016;28(7):339–348.
   PubMed Web of Science ®Google Scholar
• Reck M, Rodriguez-Abreu D, Robinson AG, et al. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N Engl J Med. 2016;375(19):1823–1833.
   PubMed Web of Science ®Google Scholar
• Leliefeld PHC, Koenderman L, Pillay J. How neutrophils shape adaptive immune responses. Front Immunol. 2015;6:471.
   PubMed Web of Science ®Google Scholar
• Donskov F, von der Maase H. Impact of immune parameters on long-term survival in metastatic renal cell carcinoma. J Clin Oncol. 2006;24(13):1997–2005.
   PubMed Web of Science ®Google Scholar